Concord Biotech Limited (CONCORDBIO) — Cash Flow Reinvestment Rate
Concord Biotech Limited (CONCORDBIO) has a Cash Flow Reinvestment Rate of 0.45x as of March 2025, reinvesting Rs1.11 Billion (capex Rs1.11 Billion ) from operating cash flow of Rs2.47 Billion. Check CONCORDBIO cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Concord Biotech Limited Cash Flow Reinvestment Rate (2020–2025)
Historical reinvestment intensity for Concord Biotech Limited across 6 annual periods. Explore cash flow to debt ratio of Concord Biotech Limited to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Concord Biotech Limited (2020–2025)
Year-by-year capital reinvestment analysis for Concord Biotech Limited. For live market cap and broader valuation context, see Concord Biotech Limited stock valuation.
| Year | Reinvestment Rate | Total Reinvested (INR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | Rs1.11 Billion | Rs2.47 Billion | Rs1.11 Billion | ▲ +39.2% |
| 2024 | 0.32x | Rs856.88 Million | Rs2.65 Billion | Rs856.88 Million | ▼ -45.3% |
| 2023 | 0.59x | Rs1.45 Billion | Rs2.46 Billion | Rs1.45 Billion | ▼ -21.3% |
| 2022 | 0.75x | Rs1.56 Billion | Rs2.07 Billion | Rs1.56 Billion | ▼ -38.8% |
| 2021 | 1.22x | Rs2.04 Billion | Rs1.67 Billion | Rs2.04 Billion | ▲ +21.9% |
| 2020 | 1.00x | Rs1.55 Billion | Rs1.55 Billion | Rs1.55 Billion | — |